Characterization of a new mouse model for human apolipoprotein A-I/C-III/A-IV deficiency Published, JLR Papers in Press, February 23, 2006.

Human data raised the possibility that coronary heart disease is associated with mutations in the apolipoprotein gene cluster APOA1/C3/A4 that result in multideficiency of cluster-encoded apolipoproteins and hypoalphalipoproteinemia. To test this hypothesis, we generated a mouse model for human apolipoprotein A-I (apoA-I)/C-III/A-IV deficiency. Homozygous mutants (Apoa1/c3/a4−/−) lacking the three cluster-encoded apolipoproteins were viable and fertile. In addition, feeding behavior and growth were apparently normal. Total cholesterol (TC), high density lipoprotein cholesterol (HDLc), and triglyceride levels in the plasma of fasted mutants fed a regular chow were 32% (P < 0.001), 17% (P < 0.001), and 70% (P < 0.01), respectively, those of wild-type mice. When fed a high-fat Western-type (HFW) diet, Apoa1/c3/a4−/− mice showed a further decrease in HDLc concentration and a moderate increase in TC, essentially in non-HDL fraction. The capacity of Apoa1/c3/a4−/− plasma to promote cholesterol efflux in vitro was decreased to 75% (P < 0.001), and LCAT activity was decreased by 38% (P < 0.01). Despite the very low total plasma cholesterol, the imbalance in lipoprotein distribution caused small but detectable aortic lesions in one-third of Apoa1/c3/a4−/− mice fed a HFW diet. In contrast, none of the wild-type mice had lesions. These results demonstrate that Apoa1/c3/a4−/− mice display clinical features similar to human apoA-I/C-III/A-IV deficiency (i.e., marked hypoalphalipoproteinemia) and provide further support for the apoa1/c3/a4 gene cluster as a minor susceptibility locus for atherosclerosis in mice.

[1]  R. F. Hoyt,et al.  Targeted Disruption of the Mouse Lecithin:Cholesterol Acyltransferase (LCAT) Gene , 1997, The Journal of Biological Chemistry.

[2]  J. Saklatvala,et al.  High-density lipoproteins differentially modulate cytokine-induced expression of E-selectin and cyclooxygenase-2. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[3]  M. Brown,et al.  Independent pathways for secretion of cholesterol and apolipoprotein E by macrophages. , 1983, Science.

[4]  P. Giral,et al.  A cell culture system for screening human serum for ability to promote cellular cholesterol efflux. Relations between serum components and efflux, esterification, and transfer. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[5]  O. Francone,et al.  Increased Atherosclerosis in Hyperlipidemic Mice With Inactivation of ABCA1 in Macrophages , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[6]  C. Bisgaier,et al.  Distribution of apolipoprotein A-IV in human plasma. , 1985, Journal of lipid research.

[7]  G. Utermann,et al.  Activation of lecithin: cholesterol acyltransferase by human apolipoprotein A-IV. , 1985, The Journal of biological chemistry.

[8]  D. Rader,et al.  Apolipoprotein A-I Deficiency Results in Markedly Increased Atherosclerosis in Mice Lacking the LDL Receptor , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[9]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[10]  N. Baroukh,et al.  Expression of Human Apolipoprotein A-I/C-III/A-IV Gene Cluster in Mice Induces Hyperlipidemia but Reduces Atherogenesis , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[11]  C. Gabel,et al.  High density lipoprotein deficiency and foam cell accumulation in mice with targeted disruption of ATP-binding cassette transporter-1. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[12]  B. Bhattacharyya,et al.  Colcemid and colchicine binding to tubulin , 1979, FEBS letters.

[13]  N. Maeda,et al.  Marked reduction of high density lipoprotein cholesterol in mice genetically modified to lack apolipoprotein A-I. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[14]  T. Langmann,et al.  Transport of lipids from Golgi to plasma membrane is defective in Tangier disease patients and Abc1-deficient mice , 2000, Nature Genetics.

[15]  J. Breslow,et al.  Decreased HDL cholesterol levels but normal lipid absorption, growth, and feeding behavior in apolipoprotein A-IV knockout mice. , 1997, Journal of lipid research.

[16]  E. Rubin,et al.  Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells , 1992, Cell.

[17]  R. Krauss,et al.  Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI , 1991, Nature.

[18]  G. Miller High density lipoproteins and atherosclerosis. , 1980, Annual review of medicine.

[19]  R. Ramakrishnan,et al.  Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E. , 1997, The Journal of clinical investigation.

[20]  J. Berliner,et al.  Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. , 1995, The Journal of clinical investigation.

[21]  R. Williams,et al.  Quantitative assessment of atherosclerotic lesions in mice. , 1987, Atherosclerosis.

[22]  J. Ordovás,et al.  Familial apolipoprotein A-I, C-III, and A-IV deficiency and premature atherosclerosis due to deletion of a gene complex on chromosome 11. , 1989, The Journal of biological chemistry.

[23]  J. Fruchart,et al.  Human apolipoprotein A-IV binds to apolipoprotein A-I/A-II receptor sites and promotes cholesterol efflux from adipose cells. , 1990, The Journal of biological chemistry.

[24]  T. Hayek,et al.  HDL Apolipoprotein A-I Attenuates Oxidative Modification of Low Density Lipoprotein: Studies in Transgenic Mice , 1995, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies.

[25]  Jonathan C. Cohen,et al.  An Apolipoprotein Influencing Triglycerides in Humans and Mice Revealed by Comparative Sequencing , 2001, Science.

[26]  N. Maeda,et al.  Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. , 1992, Science.

[27]  J. Parks,et al.  Lecithin:Cholesterol Acyltransferase Deficiency Increases Atherosclerosis in the Low Density Lipoprotein Receptor and Apolipoprotein E Knockout Mice* , 2002, The Journal of Biological Chemistry.

[28]  A. Tall,et al.  Regulation and mechanisms of macrophage cholesterol efflux. , 2002, The Journal of clinical investigation.

[29]  W. J. Johnson,et al.  Apolipoproteins, membrane cholesterol domains, and the regulation of cholesterol efflux. , 1992, Journal of lipid research.

[30]  E. Ferris,et al.  DNA inversion within the apolipoproteins AI/CIII/AIV-encoding gene cluster of certain patients with premature atherosclerosis. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[31]  S. Karathanasis Apolipoprotein multigene family: tandem organization of human apolipoprotein AI, CIII, and AIV genes. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[32]  Hao Li,et al.  Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia. , 1994, The Journal of biological chemistry.

[33]  G. Utermann,et al.  Apolipoprotein A-IV: a protein occurring in human mesenteric lymph chylomicrons and free in plasma. Isolation and quantification. , 1979, European journal of biochemistry.

[34]  C. Fielding,et al.  A protein cofactor of lecithin:cholesterol acyltransferase. , 1972, Biochemical and biophysical research communications.

[35]  L. Rudel,et al.  Differential effects of dietary fat on the tissue-specific expression of the apolipoprotein A-I gene: relationship to plasma concentration of high density lipoproteins. , 1989, Journal of lipid research.

[36]  M. Yumoto,et al.  Apolipoprotein A-I deficiency with accumulated risk for CHD but no symptoms of CHD. , 2002, Atherosclerosis.

[37]  J. Glomset,et al.  The plasma lecithins:cholesterol acyltransferase reaction. , 1968, Journal of lipid research.

[38]  P. Denéfle,et al.  Protection Against Atherogenesis in Mice Mediated by Human Apolipoprotein A-IV , 1996, Science.

[39]  S. Fazio,et al.  Prevention of atherosclerosis in apolipoprotein E-deficient mice by bone marrow transplantation , 1995, Science.

[40]  Hao Li,et al.  Lack of apoA-I is not associated with increased susceptibility to atherosclerosis in mice. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

[41]  J. Albers,et al.  Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol. , 1982, Clinical chemistry.

[42]  De-Pei Liu,et al.  The Expression of Intact and Mutant Human apoAI/CIII/AIV/AV Gene Cluster in Transgenic Mice* , 2005, Journal of Biological Chemistry.

[43]  Charles R.scriver,et al.  The Metabolic basis of inherited disease , 1989 .